|Day's range||1.0400 - 1.2000|
If you're thinking of investing in Pfizer (NYSE: PFE) to generate some passive income from your portfolio, you won't need to spend very much to do so, provided that you're willing to play the long game. Building up a passive income stream is often a lot more manageable when you can do it piece by piece rather than paying out a large lump sum. Dollar-cost averaging (DCA) refers to buying a few shares of a stock here and there over a period of time so that you don't need a lump sum to reach your target position size.
Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Novocure (NASDAQ: NVCR), and Pfizer (NYSE: PFE). David Jagielski (CRISPR Therapeutics): Shares of CRISPR Therapeutics are trading below $70, but it may not be long before they take off. The company has a promising gene-editing therapy in exa-cel for rare blood disorders beta-thalassemia and sickle cell disease that it has been working on with Vertex Pharmaceuticals.
Per the FDA, Pfizer's (PFE) Paxlovid is the first oral antiviral pill approved in the United States to treat COVID-19 in adults. The drug was granted emergency use authorization by the FDA in 2021.
Yahoo Finance Live health care reporter Anjalee Khemlani details the clinical trial results of Pfizer's weight loss drug Danuglipron, how it compares to Novo Nordisk's Ozempic, and examines the adoption of weight loss drugs in the health and wellness space.
Revised contract addresses concerns over costly glut of unwanted shots as public health threat wanes
The market wasn't impressed by the company's latest drug approval, plus an analyst cut her price target on the shares.
NEW YORK, May 25, 2023--Pfizer Inc. (NYSE: PFE) will present data across its Oncology portfolio and growing pipeline, covering multiple tumor types and novel mechanisms of action at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2 through June 6. Abstracts include new data from pivotal trials supporting ongoing regulatory reviews for three potential therapies, if approved, and new clinical data for six early pipeline assets. In addition, Pfizer will hig
Yahoo Finance health care reporter Anjalee Khemlani analyzes shares of pharmaceutical giant Pfizer as the FDA issues its full approval of the COVID-19 treatment drug Paxlovid.
Wall Street has high hopes for certain stocks over the coming 12 months. Two of them are biotech companies that took center stage during earlier days of the pandemic. Both companies raced to bring a coronavirus vaccine to market.
Pfizer (NYSE: PFE) has been a losing play for investors over the past 12 months. To wit: The drugmaker's stock has fallen by a whopping 28.8% over this period. Since the start of 2023, investors have shown a magnetic attraction to a select group of companies such as Eli Lilly (NYSE: LLY), Crispr Therapeutics, Microsoft, and Nvidia, causing their shares to dramatically outperform the broader market.
NEW YORK, May 25, 2023--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) approved PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. PAXLOVID has been available in the U.S. since December 2021 under Emergency Use Authorization (EUA), and the overall benefit/risk profile and indication for use in eligible
Allison Transmission and Alico have been highlighted as Zacks Bull and Bear of the Day.
Eat right, stay active, and tame your inner food demons -- but also inject this syringe deep into your stomach to keep the pounds off. Noom, the...
Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.
The United States is on the brink of a debt-ceiling crisis that could have devastating consequences for the global economy. Will the looming fiscal showdown shake the world?
You may know Pfizer (NYSE: PFE) for its blockbuster coronavirus vaccine. Pfizer may face a bit of a near-term slowdown in revenue. In fact, Pfizer says these launches should result in $20 billion in sales in 2030.
The Federal Trade Commission (FTC) has been taking a much more adversarial approach to mergers and acquisitions lately. For instance, it recently said it plans to block the pending deal between pharmaceutical companies Horizon Therapeutics (NASDAQ: HZNP) and Amgen (NASDAQ: AMGN). Does the FTC's recent tough stance on big deals increase the chances that Pfizer's (NYSE: PFE) acquisition of Seagen (NASDAQ: SGEN) will also run into problems?
Shares of the Danish pharma giant Novo Nordisk (NYSE: NVO) were down by 3.4% on elevated volume as of 1:14 p.m. ET Tuesday afternoon. The drugmaker's shares are falling in response to the strong mid-stage data for Pfizer's orally administered diabetes and weight loss drug, danuglipron, which were published yesterday in JAMA Network medical journal. Novo's shares have more than doubled in value over the prior two years, thanks to the breakout success of its type 2 diabetes and weight loss drug semaglutide.
Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
Data from a phase II study published in JAMA showed that Pfizer's (PFE) danuglipron reduces glycated hemoglobin and fasting plasma glucose (at all doses) and body weight (at the highest doses) at week 16.
The holy grail of pharmaceutical companies and biotechs is the development of a medication with blockbuster potential, and Pfizer seems to have one on its hands. A peer-reviewed study of Pfizer's investigational drug danuglipron found that the medication lowered both blood sugar and body weight after 16 weeks of use when compared to a placebo. Compounding that, that level of weight loss is comparable to pharmaceutical rival Novo Nordisk's (NYSE: NVO) highly successful semaglutide, a commercialized drug known in this country as either Ozempic or Rybelsus for diabetes, and Wegovy for weight loss.
Yahoo Finance Live anchors Akiko Fujita and Seana Smith break down Monday's top headlines, including Meta being fined $1.3 billion, Pfizer's weight loss study, and retailers set to report earnings on Tuesday.
Yahoo Finance's Rachelle Akuffo details a rise in Pfizer stock after the company announced positive results from the study of a new weight loss drug.
Yahoo Finance Live’s Rachelle Akuffo breaks down the top trending tickers, including Plug Power announcing three deals in Europe and Pfizer’s weight loss drug.